Supriya Lifescience Limited (SUPRIYA) Fair Value & Analysis
Healthcare · IN · Market cap ₹78.8B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +8.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹553.35 – ₹1,053 · fair‑value band ₹266.76 – ₹922.42 · the ₹978.90 price screens above the ₹520.62 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Supriya Lifescience Limited (SUPRIYA) currently trades at ₹978.90, while our model-based Fair Value estimate is ₹520.62 — implying the stock looks roughly 46.8% overvalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Supriya Lifescience Limited generated revenue of ₹8.3B at a net margin of 25.3%. Revenue grew 50.2% year over year. It earns a return on equity of 19.1%. The balance sheet holds a net cash position of ₹734M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Supriya Lifescience Limited reported revenue of ₹8.3B in FY2026 versus ₹5.2B in FY2022, a compound +12.4%/yr. Reported net income was ₹2.1B in FY2026, compounding +8.3%/yr from FY2022.
Is SUPRIYA fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Supriya Lifescience Limited (SUPRIYA) undervalued?
What is the fair value of SUPRIYA?
What is the quality score of SUPRIYA?
What is the revenue of Supriya Lifescience Limited (SUPRIYA)?
What is the net profit margin of SUPRIYA?
Does Supriya Lifescience Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.